drugset / Trial / NCT01070628
Levodopa Concentration Profile With Stalevo 75/125 mg
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels. Therefore, it is anticipated that when lower dose of Stalevo is administered after the first higher dose of Stalevo, this would result in equally high levodopa maximum concentration values (Cmax) after each dose throughout the day compared to Cmax after the first dose.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-02
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sinemet | Unknown | 100 mg | — |
| Comparator | Sinemet | Unknown | 150 mg | — |
| Subject | Stalevo | Unknown | 75 mg | — |
| Subject | Stalevo | Unknown | 100 mg | — |
| Subject | Stalevo | Unknown | 125 mg | — |
| Subject | Stalevo | Unknown | 150 mg | — |